このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

2019年11月4日 更新者:Nimbe Torres y Torres、Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Effect of Dietary Intervention on LDL-C Levels and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

The primary aim of the present study was to elucidate the effect of a combination of functional foods on the low-density lipoprotein cholesterol (LDL-C) levels and on the distribution of the lipoprotein subclasses in subjects with hypercholesterolemia. To accomplish the latter, subjects that met the inclusion criteria and had mild hypercholesterolemia (Total cholesterol >200mg/dL, and LDL-C >130mg/dL <190 mg/dL) were recruited for double-blind, parallel, controlled dietary intervention study. After two weeks of dietary standardization with an isocaloric diet, subjects were randomized and allocated to either placebo or a dietary portfolio treatment for two months. The secondary endpoints were the size of the different lipoprotein subclasses, total cholesterol levels, high density -lipoprotein cholesterol (HDL-C) levels, apolipoprotein B, triglycerides, total/HDL-C ratio, apolipoprotein B/apolipoprotein A ratio, and anthropometric measurements.

調査の概要

詳細な説明

The present work took place at the Department of Physiology of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ). The study followed a randomized, controlled, double-blind, parallel design encompassing five visits. On the first visit, volunteers were screened for eligibility criteria. Subjects that met the inclusion criteria were then invited to a second visit. Herein, volunteers received a thorough explanation of the experimental maneuver, as well as the overall objectives of the study. Thereafter, subjects who agreed to participate signed a consent form.

Upon agreement, assessment of habitual dietary intake and physical activity was obtained by 24-hour dietary recalls, food frequency questionnaire (FFQ), and by the International Physical Activity Questionnaire (IPAQ), respectively. Additionally, anthropometric measurements and blood samples were registered and collected. Then, volunteers underwent dietary standardization for two weeks with isocaloric diets (LSFD), which followed the National Cholesterol Education Program (NCEP) , Adult Treatment Panel III (ATP III) criteria. That is, 50-60% carbohydrates, 15% protein, 25-35% fat,<7% saturated fat,≤ 200mg of dietary cholesterol, 20-35g of fiber, and 2000mg/d of sodium.

On the third visit, subjects were randomly allocated to either LSFD plus placebo or an LSFD plus the dietary portfolio (DP). Of note, the prescribed diets were matched to the volunteers' habitual caloric intake -considering the energy provided by the placebo or DP- to avoid variability of the endpoint variables due to weight-loss. The DP and placebo provided 200kcal; the DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The organoleptic characteristics and packaging were similar between treatments. Subjects were instructed to consume two packets per day, preferably with breakfast and dinner. The content of each packet (30g of product) was dissolved in 250-300ml of water.

Volunteers followed the given treatment for two consecutive months, during which two follow-up visits took place. Blood samples, anthropometric characteristics, and blood pressure were obtained in all visits.

Compliance to diet, placebo, and DP was assessed with 24-hour dietary recalls, 3-day dietary records, and with the number of empty packets returned on the corresponding visits.

研究の種類

介入

入学 (実際)

62

段階

  • 適用できない

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~60年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Men and women
  • Body mass index (BMI) 25 to ≤ 39.9 kg/m2
  • Adults between 20 and 60 years of age
  • Total cholesterol levels of >200mg/dL in serum
  • LDL-C levels ≥130mg/dL ≤190mg/dL
  • Literate subjects
  • Signature of informed consent

Exclusion Criteria:

  • Subjects with diabetes
  • Diseases that produce obesity or diabetes
  • Cardiovascular events
  • Weight-loss of ≥ 3kg on the preceding months to the study
  • Catabolic diseases such as cancer and acquired immunodeficiency syndrome
  • Pregnancy and breastfeeding
  • Positive Smoking
  • Pharmacological treatment including:

Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss

  • Subjects with high cardiovascular risk
  • Subjects with symptomatic digestive pathologies

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo (P)
The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
実験的:Dietary Portfolio (DP)
The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
A mixture of functional foods divided into 30g individual packets.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Low density lipoprotein- cholesterol (LDL-C)
時間枠:Change in total LDL-C after 2.5 months of treatment
Plasma total LDL-C (mg/dl)
Change in total LDL-C after 2.5 months of treatment
Lipoprotein subclasses
時間枠:Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment
High density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.
Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Total cholesterol
時間枠:Change in total cholesterol after 2.5 months of treatment
Plasma total cholesterol (mg/dL)
Change in total cholesterol after 2.5 months of treatment
Triglycerides
時間枠:Change in triglycerides after 2.5 months of treatment
Plasma triglycerides (mg/dL)
Change in triglycerides after 2.5 months of treatment
High density lipoprotein cholesterol (HDL-C)
時間枠:Change after 2.5 months of treatment
Plasma HDL cholesterol (mg/dL)
Change after 2.5 months of treatment
Apolipoprotein B
時間枠:Change after 2.5 months of treatment
Change in apolipoprotein B in
Change after 2.5 months of treatment
Apolipoprotein A
時間枠:Change after 2.5 months of treatment
Change in apolipoprotein A in plasma
Change after 2.5 months of treatment
Total/ high density lipoprotein cholesterol (HDL-C) ratio
時間枠:Change after 2.5 months of treatment
Change in total/ high density lipoprotein cholesterol (HDL-C) ratio
Change after 2.5 months of treatment
Apolipoprotein B/Apolipoprotein A ratio
時間枠:Change after 2.5 months of treatment
Change in Apolipoprotein B / Apolipoprotein A ratio
Change after 2.5 months of treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Nimbe Torres y Torres, PhD、INCMNSZ

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2013年2月28日

一次修了 (実際)

2018年12月18日

研究の完了 (実際)

2018年12月18日

試験登録日

最初に提出

2019年10月31日

QC基準を満たした最初の提出物

2019年10月31日

最初の投稿 (実際)

2019年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2019年11月6日

QC基準を満たした最後の更新が送信されました

2019年11月4日

最終確認日

2019年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する